Voyager Pharmaceutical Corporation Announces Revised Terms for IPO
Posted on: Thursday, 8 December 2005, 09:00 CST
RALEIGH, N.C., Dec 8 /PRNewswire/ -- Voyager Pharmaceutical Corporation announced today revised terms for its upcoming IPO. The estimated price range has been lowered from $15.00-$19.00 per share to $11.00-$15.00 per share. The shares of common stock to be offered by the Company in the offering have been decreased by 1,400,000 shares such that the aggregate number of shares to be sold in the offering will now be 4,500,000 shares. Voyager Pharmaceutical is planning to go public using the OpenIPO(R) process, an online auction. Please see below for details of how to obtain a prospectus.
This press release is neither an offer to sell nor a solicitation of an offer to buy any of the securities. The offering shall only be made through a prospectus.
A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement become effective.
WR Hambrecht + Co, LLC is the sole manager of the offering, which is being made through WR Hambrecht + Co's OpenIPO(R) auction-based process. Copies of the prospectus relating to this offering may be obtained by going to WR Hambrecht + Co's Web site, http://www.wrhambrecht.com/ , by calling 800-673-6476, or by writing to WR Hambrecht + Co, P.O. Box 677, Berwyn, PA 19312.
About Voyager Pharmaceutical Corporation
Voyager Pharmaceutical Corporation is a biopharmaceutical company focused on developing drugs for diseases associated with aging and development. Voyager's scientific approach is based on the observation that many diseases of aging may be caused by changes in human reproductive hormone levels that are characteristic of the aging process. Voyager's most advanced product candidate is Memryte, a proprietary, small, biodegradable implant that is comprised of leuprolide acetate and a polymer, that it is developing for the treatment of mild to moderate Alzheimer's disease. Voyager was founded in 2001 and is headquartered in Raleigh, N.C.
Contact: Patrick Smith, President and CEO, T. 919-846-4880
Voyager Pharmaceutical Corporation
CONTACT: Patrick Smith, President and CEO, +1-919-846-4880
Web site: http://www.wrhambrecht.com/
Source: PRNewswire
Related Articles
- SISCO (Security Identification Systems Corporation) Awarded Small Business Certification by Palm Beach County, Florida
- Endo Pharmaceuticals Announces Extension of its Tender Offer for Shares of Indevus Pharmaceuticals
- American Medical Systems Completes Cash Tender Offer for Shares of Laserscope
- Voyager Pharmaceutical Corporation Announces the Formation of Its Medical And Scientific Advisory Board
- Voyager Pharmaceutical Corporation to Present at the 9th International Geneva/Springfield Symposium on Advances in Alzheimer Therapy
- Joseph DeVeaugh-Geiss, M.D., Expands Role As Interim Chief Medical Officer at Voyager Pharmaceutical Corporation
- NEC Infrontia Corporation Announces Notice of Approval of the Tender Offer for Shares of NEC Infrontia Corporation and the Stock-for-Stock Exchange
- TOSHIBA TEC CORPORATION Document Processing & Telecommunication System Company Selects Servigistics for Service Parts Management
- Mycom Group Secures Strategic Alliance Agreement With Process Software
 |
 |
User Comments (0)
RSS Feeds